Neoantigen is a protein that forms on the cancerous cells as a result on mutations in the tumorous DNA. They are thus used in development on vaccines and immunotherapies against cancer cells. Neoantigens are recognized in the body by neoantigen-specific T cell receptors (TCRs). Neoantigen-based vaccines and target therapies have shown promising results in various clinical trials, owing to the fact that they can be recognized as non-self/foreign and germline by the host’s immune system. Neoantigens find huge significance in cancer immunoediting. It is a technique used to establish dual roles of immune system with respect to tumor growth. Several studies have postulated the fact that neoantigen immunotherapy can in fact aid in controlling tumor outgrowth, facilitate cellular transformation and share immunogenicity of tumors. Furthermore, neoantigens can be divided into personalized neoantigens and shared neoantigens. Shared neoantigens are not present specifically in regards to individualized genome while personalized neontigens are targeted on specific individuals. Prediction on the number of neoantigens present involves a well thought validated algorithms to select more reliable neoepitopes. The procedure for development of neoantigen cancer vaccine involves obtaining tumorous tissues from the patient and subsequently identifying mutant genes of the tumor. Post this, RNA/DNA sequent test is carried out to select appropriate mutated antigens. Finally, these mutated antigens are designed into suitable vaccines.
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the global neoantigens market.
Top Impacting Factors
- Rise in the case of cancer and other chronic diseases coupled with growing demand for advanced therapeutic medications for quick, reliable, and sustainable treatment of cancer is anticipated to drive neoantigens market growth.
- Recent clinical advancements in biotechnology and growing investments being influx in study of neoantigens and related mechanisms is slated to further boost study of neoantigens market. The trend is more visible in regions with high skilled biotechnological human resource, more economic muscle and internet penetration.
- Inception of private sector global and regional player who are willing to spend more for design and development of novel medications for eradication or chronic diseases through more clinical trials, frequent product launches, and necessary collaborations & mergers may further fuel the market growth of neoantigens.
- However, higher cost associated with design and development of personalized cancer medicines may hamper market growth. The factor may largely be visible in regions which lack efficient healthcare infrastructure and fragile government support.
- Further optimization obstacles and clinical development delays mainly owing to shift of healthcare mechanisms towards battling COVID-19 may further hamper global neoantigen market outlook.
Key Market Trends
- North America is anticipated to show dominance in neoantigen market owing to rising cases of cancer in the region coupled with growing demand of development of advanced treatment mechanisms.
- BioNTech S.E. recently developed and launched individualized vaccine against cancer (IVAC) platform that helps in production of customized neoantigen vaccines.
- Further, Genocea Biosciences developed ATLAS platform for development of neoantigen vaccines. It makes use of an ex-vivo method to treat melanoma, carcinoma, and lung cancers.
- Agenus Inc. developed AutoSynVax (ASV) neoantigen vaccine to treat solid tumors. It is administered in addition to the adjuvant QS-21 Stimulon.
Key Benefits of the Report
- This study presents the analytical depiction of the neoantigens industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the neoantigens market share.
- The current market is quantitatively analyzed to highlight the neoantigens growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Neoantigens Report
- Which are the leading players active in the neoantigens market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the neoantigens market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What are the impacts of COVID-19 in the industry?
- What is neoantigens?
- What is the neoantigens market prediction in the future?
- What are the current trends and predicted trends?
Neoantigen Market Report Highlights
| Aspects | Details |
 By Type |
|
 By Therapeutic Specialty |
|
 By Product |
|
 By Cell |
|
 By Treatment |
|
 By Technology |
|
 By Route of Administration |
|
| By Delivery Mechanism |
|
 By Region |
|
 Key Market Players | Moderna, Inc., Merck & Co. Inc, Ziopharm Oncology, Inc., Advaxis, Inc., Gritstone Oncology, Genocea, Gradalis, Inc., Medigene AG, Achilles Therapeutics plc, Immunicum AB, Frame Cancer Therapeutics |
Loading Table Of Content...
